CERC Cerecor Inc.

3.37
-0.33  -9%
Previous Close 3.7
Open 3.71
Price To Book 8.64
Market Cap 158,268,468
Shares 46,963,937
Volume 38,175
Short Ratio
Av. Daily Volume 47,856
Stock charts supplied by TradingView

NewsSee all news

  1. Cerecor to Acquire Aevi Genomic Medicine

    -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer-Strategic Alternatives

  2. Cerecor to Acquire Aevi Genomic Medicine

    PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (NASDAQ:GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor")

  3. Cerecor Reports Third Quarter 2019 Results

    Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 MillionFirst Patient Enrolled in Diabetic OH Trial with CERC-301Completed Phase 1 Healthy Volunteer Study with CERC-802CERC-802 IND Accepted by FDA and

  4. Cerecor Announces Clinical Updates on CERC-301 and CERC-802

    - CERC-301 Enrolls First Patient in Diabetic Orthostatic Hypotension Trial -CERC-802 Completes Phase I Safety Study in Healthy Volunteers ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc.

  5. Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations

    ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data released December 5, 2016 - endpoint not met.
CERC-501
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
CERC-301
Major depressive disorder (MDD)
Phase 1 commencement of enrolment announced November 11, 2019.
CERC-301
Diabetic Orthostatic Hypotension
NDA planned of 2H 2020.
CERC 801
Phosphoglucomutase 1 (PGM1) deficiency
PK data due early 2020.
CERC-802
Healthy volunteers

Latest News

  1. Cerecor to Acquire Aevi Genomic Medicine

    -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer-Strategic Alternatives

  2. Cerecor to Acquire Aevi Genomic Medicine

    PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (NASDAQ:GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor")

  3. Cerecor Reports Third Quarter 2019 Results

    Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 MillionFirst Patient Enrolled in Diabetic OH Trial with CERC-301Completed Phase 1 Healthy Volunteer Study with CERC-802CERC-802 IND Accepted by FDA and

  4. Cerecor Announces Clinical Updates on CERC-301 and CERC-802

    - CERC-301 Enrolls First Patient in Diabetic Orthostatic Hypotension Trial -CERC-802 Completes Phase I Safety Study in Healthy Volunteers ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc.

  5. Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations

    ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today

  6. Cerecor Closes Deal to Sell Pediatric Portfolio

    ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and

  7. Cerecor To Sell Pediatric Portfolio to AYTU BioScience

    -Deal Valued in Excess of $32 Million-Eliminates Debt Associated with Avadel / Deerfield Agreement-Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards NDA Submission of CERC-801 ROCKVILLE,